ArticleJCO precision oncology2025

Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial.

Denise M Wolf et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.